Prevention of hepatitis C recurrence after liver transplantation: An update

Table 1 Outcome of hepatitis C virus liver transplanted patients treated with cyclosporine or tacrolimus-based immunosuppression in studies including protocol liver biopsie

Ref.	Time of biopsy (yr)	CyA-based regime	Tac-based regime	P value
Gane et al[142]	At 1 and 51	No hepatitis 12/109	No hepatitis   3/21	0.1
		Mild chronic hepatitis 59/109	Mild chronic hepatitis 11/21
		Moderate chronic hepatitis  30/109	Moderate chronic hepatitis  5/21
		Cirrhosis  8/109	Cirrhosis 2/21
Testa et al[143]	1	Evidence of recurrence 72/156	Evidence of recurrence  10/18	0.4
Berenguer et al[144]	1	F0   16/44	F0 17/46	NS
		F1  16/44	F1 15/46
		F3  8/44	F3 9/46
		F4  4/44	F4 5/46
Berenguer et al[37]	1	F = 3-4   27/90	F = 2-3 22/91	0.37
	≈ 2	F = 3-4 42/110	F = 3-4 36/97	0.8

¹It is not clearly specified in the paper when liver biopsies have been performed. CyA: Cyclosporine; Tac: Tacrolimus; NS: Not significant.

Table 2 Results of studies on treatment with Pegylated interferon and Ribavirin of recurrent hepatitis C after liver transplant

Ref.	Yr	Type of Study	Time since LT (mo)	n	Genotype (%)	Antiviral Therapy	SVR (%)	Discontinuation (%)
Rodriguez-Luna et al[88]	2004	Prospective, uncontrolled	4.2	19	63	Peg-IFN 0.5-1.5 μg/kg/wk + RBV 400-1000 mg daily x 48 wk after neg. RNA	26	49
Neff et al[89]	2004	Retrospective, uncontrolled	23.5	57	98	Peg-IFN 1.5 μg/kg/wk + RBV 400-600 mg daily x 48 wk	14	32
Dumortier et al[97]	2004	Prospective, uncontrolled	28	20	80	Peg-IFN 0.5-1.0 μg/kg/wk + RBV 400-1200 mg daily x 48 wk	45	20
Castells et al[107]	2005	Prospective, controlled	3.8	24	100	Peg-IFN 1.5 μg/kg/wk + RBV 400-800 mg daily x 48 wk	35	13
Berenguer et al[102]	2006	Retrospective, uncontrolled	16.6	36	89	IFN and RBV/Peg-IFN and RBV	18	40
Oton et al[103]	2006	Prospective, uncontrolled	63.3	55	91	Peg-IFN 180 μg/1.5 μg/kg/wk + RBV 11 mg/kg/d x 48 wk	24	7
Mukherjee et al[104]	2006	Retrospective, uncontrolled	16	32	75	Peg-IFN 180 μg + RBV 1000-1200 mg daily x 48 wk	34	15
Mukherjee et al[104]	2006	Prospective, uncontrolled	20	39	79	Peg-IFN 1.5 μg/kg/wk + RBV 800 mg daily x 6-12 mo	33	43
Fernandez et al[105]	2006	Prospective, uncontrolled	32	47	93	Peg-IFN 1.5 μg/kg/wk + RBV 800-1000 mg daily x 48 wk	23	21
Neumann et al[106]	2006	Prospective, uncontrolled	38	25	80	Peg-IFN 1.0 μg/kg/wk + RBV 600 mg daily x 48 wk	36	4
Picciotto et al[94]	2007	Prospective, uncontrolled	25	61	87	Peg-IFN 1 μg/kg/wk RBV 600-800 mg daily x 6-12 mo	28	15
Angelico et al[108]	2007	Prospective, controlled	48	21	81	Peg-IFN 180 μg + RBV 200-800 mg daily x 48 wk	33	55
Carriòn et al[140]	2007	Prospective, controlled	14.5	54	92	Peg-IFN 1.5 μg/kg/wk + 400-1200 mg daily x 48 wk	33	39
Sharma et al[141]	2007	Retrospective, uncontrolled	16	35	77	Peg-IFN 90-180 μg/0.5-1.5 μg/kg/wk + RBV 800 mg daily x 48 wk	37	74
Zimmermann et al[107]	2007	Prospective, uncontrolled	9.4	26	88	90 μg/wk for 4 wk then 135-180 μg/wk + 600 mg for 5 wk, then 800–1200 mg x 48 wk	19	11

LT: Liver transplant; IFN: Interferon; Peg: Pegylated; RBV: Ribavirin; SVR: Sustained virological response.